海思科(002653.SZ)创新药HSK39297片新适应症IND申请获受理

Core Viewpoint - The company received a notice from the National Medical Products Administration regarding the acceptance of its drug application for HSK39297 tablets, targeting age-related macular degeneration and generalized myasthenia gravis [1] Group 1 - The drug HSK39297 has clear targets, confirmed efficacy, and good safety, indicating strong development potential as a small molecule drug [1] - Preclinical research results suggest a high benefit/risk ratio for clinical application, highlighting its promising clinical application prospects [1] - The drug is expected to become an effective treatment for AMD and gMG, addressing the current shortage of clinical medications in these areas [1]